Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT03804944
This study is recruiting at 5 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 90 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Weill Medical College of Cornell University
- Last updated on ClinicalTrials.gov
- January 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 3
- Brooklyn Methodist Hospital - NewYork Presbyterian · New York, NY
- New York Presbyterian Hospital - Queens · New York, NY
- Weill Cornell Medicine New York Presbyterian Hospital · New York, NY
Texas · 2
- UT Southwestern Medical Center · Dallas, TX
- Houston Methodist Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.